FLNA
Filana Therapeutics, Inc.
Healthcare — Biotechnology
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
Price History
Fundamentals
| Market Cap | $60.38M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-1.61 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -79.59% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $6.50 |
| Analysts | 2 |
| Next Earnings | Jul 29, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 41.0 |
| Beta | -0.78 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $4.98 |
| 52-Week Low | $1.15 |
| 50-Day Avg | $1.35 |
| 200-Day Avg | $2.26 |
| Avg Volume | 383.7K |
| Volume | 429.8K |
Performance Analysis
NEUTRALFLNA presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:09 UTC
Back to Screener Export Report